164 related articles for article (PubMed ID: 38782182)
1. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch M; Roden M; Kahl S
Metabolism; 2024 May; ():155937. PubMed ID: 38782182
[TBL] [Abstract][Full Text] [Related]
2. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
; ; ;
Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
[TBL] [Abstract][Full Text] [Related]
3. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
; ;
Obes Facts; 2024 Jun; ():1-70. PubMed ID: 38852583
[TBL] [Abstract][Full Text] [Related]
4. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
; ; ;
J Hepatol; 2024 Jun; ():. PubMed ID: 38851997
[TBL] [Abstract][Full Text] [Related]
5. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
[TBL] [Abstract][Full Text] [Related]
6. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
[TBL] [Abstract][Full Text] [Related]
7. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges.
Xie C; Alkhouri N; Elfeki MA
World J Hepatol; 2024 May; 16(5):731-750. PubMed ID: 38818288
[TBL] [Abstract][Full Text] [Related]
8. The first MASH drug therapy on the horizon: Current perspectives of resmetirom.
Petta S; Targher G; Romeo S; Pajvani UB; Zheng MH; Aghemo A; Valenti LVC
Liver Int; 2024 Jul; 44(7):1526-1536. PubMed ID: 38578141
[TBL] [Abstract][Full Text] [Related]
9. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
Burmeister Y; Weyer K; Dörre A; Seilheimer B
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
[TBL] [Abstract][Full Text] [Related]
10. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
Abushamat LA; Shah PA; Eckel RH; Harrison SA; Barb D
Clin Gastroenterol Hepatol; 2024 Feb; ():. PubMed ID: 38367743
[TBL] [Abstract][Full Text] [Related]
11. Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.
Giannakogeorgou A; Roden M
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S52-S75. PubMed ID: 38813830
[TBL] [Abstract][Full Text] [Related]
12. Incretin-based investigational therapies for the treatment of MASLD/MASH.
Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
[TBL] [Abstract][Full Text] [Related]
13. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
Zeng J; Fan JG; Francque SM
United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
[TBL] [Abstract][Full Text] [Related]
15. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
Armandi A; Bugianesi E
Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
[TBL] [Abstract][Full Text] [Related]
16. The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes.
Castellano-Castillo D; Núñez-Sánchez MÁ; Balaguer-Román A; Martínez-Sánchez MA; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez CM; Frutos MD; Queipo-Ortuño MI; Cardona F; Ramos-Molina B
Surg Obes Relat Dis; 2024 Jul; 20(7):652-659. PubMed ID: 38490825
[TBL] [Abstract][Full Text] [Related]
17. Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.
Zhang F; Lo EKK; Chen J; Wang K; Felicianna ; Ismaiah MJ; Leung HKM; Zhao D; Lee JC; El-Nezami H
J Agric Food Chem; 2024 Apr; 72(15):8536-8549. PubMed ID: 38575146
[TBL] [Abstract][Full Text] [Related]
18. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
19. Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.
Ciardullo S; Muraca E; Vergani M; Invernizzi P; Perseghin G
Gastroenterol Rep (Oxf); 2024; 12():goae029. PubMed ID: 38681750
[TBL] [Abstract][Full Text] [Related]
20. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
López-Pascual E; Rienda I; Perez-Rojas J; Rapisarda A; Garcia-Llorens G; Jover R; Castell JV
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
